SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-124979
Filing Date
2021-10-12
Accepted
2021-10-12 06:59:24
Documents
16
Period of Report
2021-10-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2129361d1_8k.htm   iXBRL 8-K 57531
2 EXHIBIT 2.1 tm2129361d1_ex2-1.htm EX-2.1 799341
3 EXHIBIT 99.1 tm2129361d1_ex99-1.htm EX-99.1 42453
7 GRAPHIC tm2129361d1_ex99-1img004.jpg GRAPHIC 4002
8 GRAPHIC tm2129361d1_ex99-1img005.jpg GRAPHIC 2619
  Complete submission text file 0001104659-21-124979.txt   1281213

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA adms-20211010.xsd EX-101.SCH 3201
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE adms-20211010_lab.xml EX-101.LAB 34594
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adms-20211010_pre.xml EX-101.PRE 22721
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2129361d1_8k_htm.xml XML 3617
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 211316840
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences